Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
NGHIÊN CỨU LÂM SÀNG Issue: Số 117

Short-term outcomes of drug-coated balloon angioplasty for coronary artery lesions at Huu Nghi Hospital

Bùi Long: Bệnh viện Hữu Nghị;
Published: September 30, 2025
Views: 48

Abstract

Objective: To evaluate the short-term outcomes of drug-coated balloon treatment for coronary artery lesions and identify factors influencing the degree of restenosis after DCB treatment.

Methods: Prospective, cross-sectional study. After 12 months, the patients had a follow-up coronary angiography to evaluate the lesions.

Results: With 56 drug-coated balloon angioplasty procedures performed on 56 patients, DCB treatment for in-stent restenosis lesions accounted for the majority of cases at 67,86%. Before the procedure, 4 lesions (7,14%) had TIMI 0 flow, 3 lesions (5,36%) had TIMI 1 flow, and 19 lesions (33,93%) had TIMI 2 flow. The mean stenosis of the lesions in the study group was 83,19 ± 10,20%. After DCB angioplasty, most lesions achieved TIMI 3 flow, with a rate of 96,43%. The mean diameter stenosis decreased to 11,94 ± 8,41% after DCB treatment. The procedural success rate was 100%. A total of 31 out of 56 (55,3%) patients underwent follow-up angiography to check the treated lesion after 12 months. The mean restenosis rate after 12 months was 47,78 ± 30,60%, and the mean late lumen loss was 0,43 ± 0,36mm. A history of in-stent restenosis, multiple stents in the same branch, long total stent length, long lesion length, and in-stent restenosis were all factors influencing the degree of restenosis after 12 months. In multivariable regression analysis, multiple stents and long lesion length were found to be statistically significant factors influencing the degree of restenosis (p<0,05).

Conclusion: The study demonstrates that coronary artery intervention with DCB at Huu Nghi Hospital is highly effective, with a procedural success rate of 100%. After the intervention, the degree of vessel stenosis was significantly reduced from 83,19% to 11,94%. The 12-month follow-up showed a mean restenosis rate of 47,78%. Factors including having multiple stents and a long lesion length were independent predictors of restenosis after drug-eluting balloon angioplasty.

References

1.
Koiwaya H, Watanabe N, Kuriyama N, et al. Predictors of Recurrent In-Stent Restenosis After Paclitaxel-Coated Balloon Angioplasty. Circ J. 2017;81(9):1286-1292. doi:10.1253/circj.CJ-17-0095
2.
Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381(9865):461-467. doi:10.1016/S0140-6736(12)61964-3
3.
Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study. EuroIntervention. 2015;11(8):926-934. doi:10.4244/EIJY14M08_12
4.
Xia HY, Low AF, Lee CH, et al. Treatment of coronary in-stent restenosis with drug-eluting balloon catheter: real-world outcome and literature review. Ann Acad Med Singap. 2013;42(1):49-51.
5.
Mathey DG, Wendig I, Boxberger M, Bonaventura K, Kleber FX. Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention. 2011;7 Suppl K:K61-K65. doi:10.4244/EIJV7SKA11
6.
Vaquerizo B, Serra A, Miranda-Guardiola F, et al. One-year outcomes with angiographic follow-up of paclitaxel-eluting balloon for the treatment of in-stent restenosis: insights from Spanish multicenter registry. J Interv Cardiol. 2011;24(6):518-528. doi:10.1111/j.1540-8183.2011.00667.x
7.
Hung NM. Study on the Efficacy of Drug-Coated Balloon Angioplasty for Certain Coronary Artery Lesions, Hanoi Medical University. 2019
8.
Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119(23):2986-2994. doi:10.1161/CIRCULATIONAHA.108.839282
9.
Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2008;97(10):773-781. doi:10.1007/s00392-008-0682-5
10.
Verheye S, Vrolix M, Kumsars I, et al. The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic Results and 1-Year Clinical Outcomes. JACC Cardiovasc Interv. 2017;10(20):2029-2037. doi:10.1016/j.jcin.2017.06.021
11.
Caiazzo G, Oliva A, Testa L, et al. Sirolimus-coated balloon in all-comer population of coronary artery disease patients: the EASTBOURNE DIABETES prospective registry. Cardiovasc Diabetol. 2024;23(1):52. doi:10.1186/s12933-024-02139-9
12.
Yang JQ, Peng JH, Xu T, et al. Meta-analysis of the effects of drug-coated balloons among patients with small-vessel coronary artery disease. Medicine (Baltimore). 2019;98(22):e15797. doi:10.1097/MD.0000000000015797
13.
Xue W, Ma J, Yu X, et al. Analysis of the incidence and influencing factors associated with binary restenosis of target lesions after drug-coated balloon angioplasty for patients with in-stent restenosis. BMC Cardiovasc Disord. 2022;22(1):493. doi:10.1186/s12872-022-02923-z
14.
Cassese S, Xu B, Habara S, et al. Incidence and predictors of reCurrent restenosis after drug-coated balloon Angioplasty for Restenosis of a drUg-eluting Stent: The ICARUS Cooperation. Rev Esp Cardiol (Engl Ed). 2018;71(8):620-627. doi:10.1016/j.rec.2017.08.005

Files

Article Views48
Document Views0
Downloads0
Section NGHIÊN CỨU LÂM SÀNG
Issue Số 117
Pages 114-127